Skip to main content

Sotylize FDA Approval History

FDA Approved: Yes (First approved October 22, 2014)
Brand name: Sotylize
Generic name: sotalol hydrochloride
Dosage form: Oral Solution
Company: Arbor Pharmaceuticals, LLC
Treatment for: Ventricular Arrhythmia, Atrial Fibrillation, Atrial Flutter

Sotylize (sotalol hydrochloride) is an antiarrhythmic indicated for the treatment of ventricular arrhythmias and the maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation/flutter.

Development timeline for Sotylize

DateArticle
Oct 23, 2014Approval Arbor Pharmaceuticals Announces FDA Approval of Sotylize

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.